FDA accepts Bayer’s application to expand NUBEQA’s use in prostate cancer treatment
The U.S. Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for NUBEQA (darolutamide), potentially broadening its use for patients with ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
Ami Organics bolsters collaboration with Fermion, signs agreement for new pharma intermediates
Ami Organics Limited, a global leader in manufacturing advanced pharmaceutical intermediates and specialty chemicals, has signed a definitive agreement with Fermion, a subsidiary of Orion ... Read More
Ami Organics wins multi-million Euro supply contract from Fermion
Ami Organics has signed a multi-year, multi-tonne agreement with Fermion, a wholly-owned subsidiary of Finland-based Orion Corporation for the supply of an intermediate for its ... Read More
Merck signs $290m deal with Orion Corporation for mCRPC candidate ODM-208
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that ... Read More